Chunghwa Chemical Synthesis & Biotech Co Ltd Total Liabilities
Chunghwa Chemical Synthesis & Biotech Co Ltd total liabilities. Based on the latest financial reports, Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) has total liabilities worth NT$1.28 Billion TWD (≈ $40.20 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Chunghwa Chemical Synthesis & Biotech Co liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Chunghwa Chemical Synthesis & Biotech Co Ltd (2008–2025)
Total liabilities of Chunghwa Chemical Synthesis & Biotech Co Ltd from 2008 to 2025. This chart illustrates how Chunghwa Chemical Synthesis & Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Chunghwa Chemical Synthesis & Biotech Co to see how much of total assets are deployed in long-term investments.
Chunghwa Chemical Synthesis & Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Chunghwa Chemical Synthesis & Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Resource Mining Corporation Ltd
AU:RMI
|
Australia | AU$586.09K |
|
Pulmonx Corp
NASDAQ:LUNG
|
USA | $75.54 Million |
|
RBZ Jewellers Limited
NSE:RBZJEWEL
|
India | Rs-3.00 Billion |
|
Kilitch Drugs (India) Limited
NSE:KILITCH
|
India | Rs1.34 Billion |
|
Gowing Bros Ltd
AU:GOW
|
Australia | AU$132.17 Million |
|
Hitech Corporation Limited
NSE:HITECHCORP
|
India | Rs1.95 Billion |
|
Formosa Prosonic Industries
KLSE:9172
|
Malaysia | RM102.68 Million |
|
Ribbon Acquisition Corp Unit
NASDAQ:RIBBU
|
USA | $2.61 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Chunghwa Chemical Synthesis & Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Chunghwa Chemical Synthesis & Biotech Co.
Liquidity & Leverage Metrics
Chunghwa Chemical Synthesis & Biotech Co Ltd Total Liabilities Ratios Explained
Chunghwa Chemical Synthesis & Biotech Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chunghwa Chemical Synthesis & Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chunghwa Chemical Synthesis & Biotech Co Ltd (2008–2025)
The table below shows the annual total liabilities of Chunghwa Chemical Synthesis & Biotech Co Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$1.23 Billion ≈ $38.75 Million |
-12.50% |
| 2024-12-31 | NT$1.41 Billion ≈ $44.29 Million |
-22.82% |
| 2023-12-31 | NT$1.82 Billion ≈ $57.38 Million |
+32.84% |
| 2022-12-31 | NT$1.37 Billion ≈ $43.20 Million |
-7.76% |
| 2021-12-31 | NT$1.49 Billion ≈ $46.83 Million |
+129.23% |
| 2020-12-31 | NT$648.48 Million ≈ $20.43 Million |
-54.45% |
| 2019-12-31 | NT$1.42 Billion ≈ $44.85 Million |
+15.05% |
| 2018-12-31 | NT$1.24 Billion ≈ $38.99 Million |
-23.93% |
| 2017-12-31 | NT$1.63 Billion ≈ $51.25 Million |
+70.43% |
| 2016-12-31 | NT$954.48 Million ≈ $30.07 Million |
-5.20% |
| 2015-12-31 | NT$1.01 Billion ≈ $31.72 Million |
-36.74% |
| 2014-12-31 | NT$1.59 Billion ≈ $50.14 Million |
+19.74% |
| 2013-12-31 | NT$1.33 Billion ≈ $41.88 Million |
-0.80% |
| 2012-12-31 | NT$1.34 Billion ≈ $42.21 Million |
+91.80% |
| 2011-12-31 | NT$698.59 Million ≈ $22.01 Million |
+1.57% |
| 2010-12-31 | NT$687.80 Million ≈ $21.67 Million |
-38.48% |
| 2009-12-31 | NT$1.12 Billion ≈ $35.22 Million |
-22.31% |
| 2008-12-31 | NT$1.44 Billion ≈ $45.34 Million |
-- |
About Chunghwa Chemical Synthesis & Biotech Co Ltd
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DM… Read more